Your browser doesn't support javascript.
loading
PRG4 deficiency in mice alters skeletal structure, mechanics, and calvarial osteoclastogenesis, and rhPRG4 inhibits in vitro osteoclastogenesis.
Tanguay, Adam P; Menon, Nikhil G; Boudreau, Margaret H; Jastrzebski, Sandra; Woods, Paige S; Doyle, Erica A; Edwards, W Brent; Jay, Gregory D; Deymier, Alix C; Lorenzo, Joseph; Lee, Sun-Kyeong; Schmidt, Tannin A.
Afiliação
  • Tanguay AP; Department of Biomedical Engineering, UConn Health, Farmington, Connecticut, USA.
  • Menon NG; Department of Biomedical Engineering, UConn Health, Farmington, Connecticut, USA.
  • Boudreau MH; Department of Medicine, UConn Health, Farmington, Connecticut, USA.
  • Jastrzebski S; Department of Medicine, UConn Health, Farmington, Connecticut, USA.
  • Woods PS; Department of Orthopaedic Surgery, UConn Health, Farmington, Connecticut, USA.
  • Doyle EA; Department of Biomedical Engineering, UConn Health, Farmington, Connecticut, USA.
  • Edwards WB; Department of Biomedical Engineering, UConn Health, Farmington, Connecticut, USA.
  • Jay GD; Human Performance Laboratory, Faculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.
  • Deymier AC; Department of Medicine, Brown University Warren Alpert Medical School, Providence, Rhode Island, USA.
  • Lorenzo J; Department of Engineering, Brown University Warren Alpert Medical School, Providence, Rhode Island, USA.
  • Lee SK; Department of Biomedical Engineering, UConn Health, Farmington, Connecticut, USA.
  • Schmidt TA; Department of Medicine, UConn Health, Farmington, Connecticut, USA.
J Orthop Res ; 42(6): 1231-1243, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38111181
ABSTRACT
Osteoporosis is a chronic disease characterized by reduced bone mass and increased fracture risk, estimated to affect over 10 million people in the United States alone. Drugs used to treat bone loss often come with significant limitations and/or long-term safety concerns. Proteoglycan-4 (PRG4, also known as lubricin) is a mucin-like glycoprotein best known for its boundary lubricating function of articular cartilage. In more recent years, it has been shown that PRG4 has anti-inflammatory properties, contributes to the maintenance of subchondral bone integrity, and patients with PRG4 mutations are osteopenic. However, it remains unknown how PRG4 impacts mechanical and material properties of bone. Therefore, our objective was to perform a phenotyping study of bone in a Prg4 gene trap (GT) mouse (PRG4 deficient). We found that femurs of Prg4 GT mice have altered mechanical, structural, and material properties relative to wildtype littermates. Additionally, Prg4 GT mice have a greater number of calvarial osteoclasts than wildtype mice, but do not have a notable inflammatory serum profile. Finally, Prg4 GT mice do not have an altered rate of bone formation, and exogenous recombinant human PRG4 (rhPRG4) administration inhibited osteoclastogenesis in vitro, suggesting that the skeletal phenotype may be due to changes in bone resorption. Overall, this work demonstrates that PRG4 deficiency affects several integral properties of bone structure, mechanics, and skeletal cell activity, and provides the foundation and insight toward future work evaluating PRG4 as a potential therapeutic target in treating bone loss.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteoclastos / Osteogênese / Proteoglicanas Limite: Animals / Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteoclastos / Osteogênese / Proteoglicanas Limite: Animals / Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article